Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$33.25
-0.6%
$26.80
$14.80
$40.47
$2.53B0.87972,426 shs617,446 shs
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$28.23
+0.3%
$10.38
$8.94
$11.70
$521.02M0.08102,067 shs5,913 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.94
-38.9%
$9.70
$0.65
$34.77
$1.86B33.963.08 million shs4.34 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.59
-2.4%
$5.37
$3.79
$12.36
$1.99B0.9123.99 million shs9.45 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-0.65%+21.89%+34.69%+27.85%-11.76%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
+0.52%+0.75%+2.40%+7.34%+18,061.29%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
+77.19%+74.51%-15.57%-55.94%+807,999,900.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+1.73%+0.86%-12.31%-12.96%-23.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$33.25
-0.6%
$26.80
$14.80
$40.47
$2.53B0.87972,426 shs617,446 shs
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$28.23
+0.3%
$10.38
$8.94
$11.70
$521.02M0.08102,067 shs5,913 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.94
-38.9%
$9.70
$0.65
$34.77
$1.86B33.963.08 million shs4.34 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.59
-2.4%
$5.37
$3.79
$12.36
$1.99B0.9123.99 million shs9.45 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-0.65%+21.89%+34.69%+27.85%-11.76%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
+0.52%+0.75%+2.40%+7.34%+18,061.29%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
+77.19%+74.51%-15.57%-55.94%+807,999,900.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+1.73%+0.86%-12.31%-12.96%-23.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.92
Moderate Buy$53.9162.12% Upside
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
0.00
N/AN/AN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
3.00
Buy$8.0061.94% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.40
Hold$7.2558.12% Upside

Current Analyst Ratings Breakdown

Latest LCAP, NAKA, CGON, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/8/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$75.00
9/5/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$75.00
9/3/2025
KindlyMD, Inc. stock logo
NAKA
KindlyMD
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
9/1/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/18/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$55.00
7/16/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$68.00 ➝ $53.00
7/10/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy$40.00
7/8/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
7/3/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageEqual Weight$5.00
6/17/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$52.00 ➝ $56.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$551K4,601.59N/AN/A$9.63 per share3.45
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/A$1.37 per share20.64($2.85) per shareN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$2.72M683.10N/AN/A$0.43 per share11.49
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$58.84M33.83N/AN/A$2.61 per share1.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$3.21MN/A0.00N/AN/A-44.30%1.39%N/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-$3.62M-$0.86N/AN/A-244.00%-131.09%-106.04%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)

Latest LCAP, NAKA, CGON, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A
8/5/2025Q2 2025
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A-$0.34N/A-$0.35N/A$0.41 million
8/5/2025Q2 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/AN/AN/AN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.15
22.15
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
0.05
0.05
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A
13.00
13.00
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.02
3.58
3.58

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
19.40%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
40.79%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.25 millionN/AOptionable
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
318.45 million14.87 millionNot Optionable
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A376.12 million222.70 millionN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400434.15 million397.55 millionOptionable

Recent News About These Companies

Recursion to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$33.25 -0.22 (-0.65%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Lionheart Acquisition Co. II stock logo

Lionheart Acquisition Co. II NASDAQ:LCAP

Lionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.

KindlyMD stock logo

KindlyMD NASDAQ:NAKA

$4.94 -3.14 (-38.86%)
As of 01:56 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$4.58 -0.12 (-2.45%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.